CY1123909T1 - Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) - Google Patents

Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)

Info

Publication number
CY1123909T1
CY1123909T1 CY20201101064T CY201101064T CY1123909T1 CY 1123909 T1 CY1123909 T1 CY 1123909T1 CY 20201101064 T CY20201101064 T CY 20201101064T CY 201101064 T CY201101064 T CY 201101064T CY 1123909 T1 CY1123909 T1 CY 1123909T1
Authority
CY
Cyprus
Prior art keywords
receptor
interleukin
antibodies against
preparations containing
containing antibodies
Prior art date
Application number
CY20201101064T
Other languages
English (en)
Inventor
Daniel B. Dix
Kenneth S. Graham
Douglas E. Kamen
Scott M. Walsh
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44258720&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123909(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1123909T1 publication Critical patent/CY1123909T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/065—Rigid ampoules, e.g. glass ampoules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Η παρούσα εφεύρεση παρέχει φαρμακευτικά σκευάσματα που περιλαμβάνουν ένα ανθρώπινο αντίσωμα το οποίο δεσμεύεται ειδικά με τον υποδοχέα της ανθρώπινης ιντερλευκίνης-6 (hIL-6R). Τα σκευάσματα μπορεί να περιέχουν, επιπλέον ενός αντισώματος αντι-hlL-oR, τουλάχιστον ένα αμινοξύ, τουλάχιστον ένα σάκχαρο ή/και τουλάχιστον ένα μη ιοντικό επιφανειοδραστικό. Τα φαρμακευτικά σκευάσματα της παρούσας εφεύρεσης εμφανίζουν σημαντικό βαθμό σταθερότητας του αντισώματος μετά την αποθήκευση για αρκετούς μήνες.
CY20201101064T 2010-01-08 2020-11-11 Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) CY1123909T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29322710P 2010-01-08 2010-01-08
EP11703294.6A EP2521536B9 (en) 2010-01-08 2011-01-07 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
US12/986,223 US9173880B2 (en) 2010-01-08 2011-01-07 Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
PCT/US2011/020457 WO2011085158A2 (en) 2010-01-08 2011-01-07 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies

Publications (1)

Publication Number Publication Date
CY1123909T1 true CY1123909T1 (el) 2022-03-24

Family

ID=44258720

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181101111T CY1121420T1 (el) 2010-01-08 2018-10-30 Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
CY20201101064T CY1123909T1 (el) 2010-01-08 2020-11-11 Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181101111T CY1121420T1 (el) 2010-01-08 2018-10-30 Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)

Country Status (39)

Country Link
US (4) US9173880B2 (el)
EP (4) EP2521536B9 (el)
JP (2) JP5805660B2 (el)
KR (1) KR101787351B1 (el)
CN (1) CN102869346B (el)
AR (1) AR079836A1 (el)
AU (1) AU2011204311B2 (el)
BR (1) BR112012016618A2 (el)
CA (1) CA2790197C (el)
CL (1) CL2012001853A1 (el)
CO (1) CO6592078A2 (el)
CR (1) CR20120393A (el)
CY (2) CY1121420T1 (el)
DK (3) DK3756652T3 (el)
DO (1) DOP2012000193A (el)
EC (1) ECSP12012092A (el)
ES (3) ES2688070T3 (el)
GT (1) GT201200223A (el)
HR (3) HRP20221139T1 (el)
HU (3) HUE040403T2 (el)
JO (1) JO3417B1 (el)
LT (3) LT3756652T (el)
MA (1) MA33993B1 (el)
MX (1) MX2012007794A (el)
MY (1) MY156702A (el)
NI (1) NI201200119A (el)
NZ (1) NZ601114A (el)
PE (2) PE20170948A1 (el)
PL (3) PL3756652T3 (el)
PT (3) PT3409269T (el)
RS (3) RS61045B1 (el)
RU (1) RU2554779C2 (el)
SG (1) SG182283A1 (el)
SI (3) SI2521536T1 (el)
TW (2) TWI587870B (el)
UA (1) UA107211C2 (el)
UY (1) UY33169A (el)
WO (1) WO2011085158A2 (el)
ZA (1) ZA201205035B (el)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG188487A1 (en) 2010-09-17 2013-05-31 Baxter Int Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
KR101867279B1 (ko) 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR20200039028A (ko) * 2011-10-11 2020-04-14 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
MX357393B (es) * 2012-01-23 2018-07-06 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
ES2702246T3 (es) * 2012-03-26 2019-02-28 Sanofi Sa Formulaciones de agente de unión IgG4 estables
KR20150070384A (ko) * 2012-10-25 2015-06-24 메디뮨 엘엘씨 안정한 저점도 항체 제제
SG10201608703SA (en) 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
MX2017000627A (es) 2014-07-16 2017-04-27 Sanofi Biotechnology Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MA51554A (fr) 2014-11-07 2020-11-18 Sesen Bio Inc Anticorps il-6 améliorés
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
WO2017147293A1 (en) * 2016-02-23 2017-08-31 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
KR20180114955A (ko) 2016-03-07 2018-10-19 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염의 치료를 위한 조성물 및 방법
EP3216461A1 (en) 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
BR112019005328A2 (pt) 2016-09-27 2019-06-18 Fresenius Kabi Deutschland Gmbh composição farmacêutica líquida
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
WO2018081754A1 (en) * 2016-10-29 2018-05-03 University Of Miami Anti-zika virus antibodies
CN110062620B (zh) 2016-10-31 2023-12-05 德国费森尤斯卡比有限公司 液体药物组合物
MX2019007564A (es) * 2016-12-23 2019-09-06 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion corriente abajo y formulaciones de anticuerpos estables obtenidas a partir de los mismos.
AU2018214554C1 (en) 2017-02-01 2022-12-15 Novo Nordisk A/S Treatment of diuretic resistance
TW201934570A (zh) 2017-07-06 2019-09-01 美商雷傑納榮製藥公司 供製備糖蛋白之細胞培養方法
CN109350740B (zh) * 2017-11-30 2023-06-20 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
MX2020006639A (es) 2017-12-22 2020-09-14 Regeneron Pharma Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
EP3746471A1 (en) 2018-01-31 2020-12-09 Regeneron Pharmaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
EP4317959A3 (en) 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
MX2021002279A (es) 2018-08-27 2021-05-27 Regeneron Pharma Uso de espectroscopia raman en la purificacion corriente abajo.
MA53481A (fr) 2018-08-29 2021-07-07 Regeneron Pharma Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
CN112601963A (zh) 2018-08-30 2021-04-02 瑞泽恩制药公司 用于表征蛋白质复合物的方法
CA3117245A1 (en) * 2018-10-31 2020-05-07 Richter Gedeon Nyrt. Aqueous pharmaceutical formulations
MX2021008589A (es) 2019-01-16 2021-08-11 Regeneron Pharma Metodos para identificar tioles libres en proteinas.
JP2022519828A (ja) 2019-01-31 2022-03-25 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CN113785203A (zh) 2019-05-13 2021-12-10 里珍纳龙药品有限公司 改进的竞争性配体结合测定
BR112021024445A2 (pt) 2019-06-04 2022-02-15 Regeneron Pharma Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide
CN114375205A (zh) 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
MX2022003438A (es) 2019-09-24 2022-04-19 Regeneron Pharma Sistemas y metodos para uso y regeneracion de cromatografia.
BR112022009974A2 (pt) 2019-11-25 2022-08-16 Regeneron Pharma Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
WO2021163549A1 (en) 2020-02-14 2021-08-19 Sanofi Biotechnology Compositions and methods for treating viral infections
AU2021281119A1 (en) 2020-05-26 2023-02-02 Sanofi Biotechnology Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
AU2021279412A1 (en) 2020-05-29 2023-02-02 Sanofi Biotechnology Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis
JP2023533963A (ja) * 2020-07-08 2023-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｔｌａ－４抗体を含む安定化製剤
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
US20220257707A1 (en) 2020-12-17 2022-08-18 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CN116761880A (zh) 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
EP4302098A1 (en) 2021-03-03 2024-01-10 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
TW202314240A (zh) 2021-06-01 2023-04-01 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
CN117858722A (zh) * 2021-08-18 2024-04-09 百奥泰生物制药股份有限公司 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
WO2023044139A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CA3230985A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Ph meter calibration and correction
US20230129265A1 (en) 2021-10-26 2023-04-27 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1007208A (en) 1911-07-21 1911-10-31 Axel W Johnson Window.
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
DE122009000023I2 (de) 1989-07-20 2010-12-16 Kishimoto Antikörper gegen menschlichen Interleukin-6-Rezeptor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) * 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
DE07006112T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0672144A1 (en) 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1996011020A1 (fr) 1994-10-07 1996-04-18 Chugai Seiyaku Kabushiki Kaisha Medicament contre la polyarthrite rhumatoide contenant un antagoniste d'interleukine 6 comme principe actif
WO1995009873A1 (en) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
WO1996012503A1 (fr) 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remede contre des maladies provoquees par la production d'il-6
DE69525971T3 (de) 1994-12-29 2013-01-10 Chugai Seiyaku K.K. Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin
ES2264135T3 (es) 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6046223A (en) 1996-02-26 2000-04-04 Advanced Research & Technology Institute Treatment of macular edema
PT923941E (pt) 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CA2296322A1 (en) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
EP1074268B1 (en) 1998-03-17 2008-01-16 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies
CA2341239C (en) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
AU7824900A (en) 1999-10-07 2001-04-23 Eli Lilly And Company Compounds and methods for inhibiting mrp1
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
PT1314437E (pt) * 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
KR100824824B1 (ko) 2000-10-25 2008-04-23 추가이 세이야쿠 가부시키가이샤 아이엘-6 안타고니스트를 유효 성분으로서 함유하는건선의 예방 또는 치료제
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
JP2007528691A (ja) 2001-11-14 2007-10-18 セントカー・インコーポレーテツド 抗ｉｌ−６抗体、組成物、方法および使用
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
DK1613350T3 (da) 2003-04-09 2009-06-22 Genentech Inc Behandling af autoimmun sygdom hos en patient med et utilstrækkeligt respons på en TNF-alfa-inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005028514A1 (en) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
WO2005115359A2 (en) 2004-05-06 2005-12-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JPWO2006046661A1 (ja) 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−６阻害剤
CA2591587A1 (en) 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
JP2009516692A (ja) 2005-11-22 2009-04-23 ワイス 免疫グロブリン融合タンパク質製剤
PL2481753T3 (pl) 2005-12-13 2018-09-28 Eli Lilly And Company Przeciwciała anty-IL-17
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
RS52643B (en) 2006-06-02 2013-06-28 Regeneron Pharmaceuticals Inc. HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US20100158925A1 (en) 2006-06-14 2010-06-24 Meera Agarkhed Lyophilized formulations of anti-egfr antibodies
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
EP4238993A3 (en) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010106812A1 (en) * 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP5904645B2 (ja) 2010-05-07 2016-04-13 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連病態の治療のための方法
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX2016006595A (es) 2013-11-22 2016-09-06 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y metodos de uso de las mismas.
BR112016022318A2 (pt) 2014-03-27 2017-10-31 Dyax Corp método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
US20170252434A1 (en) 2014-09-16 2017-09-07 Sanofi Biotechnology Compositions for improving the health related quality of life of rheumatoid arthritis patients
JP7272794B2 (ja) 2015-11-03 2023-05-12 サノフィ・バイオテクノロジー ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法
KR20180114955A (ko) 2016-03-07 2018-10-19 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
SI3756652T1 (sl) 2022-10-28
ECSP12012092A (es) 2012-09-28
PE20170948A1 (es) 2017-07-13
HUE059811T2 (hu) 2022-12-28
TW201617095A (zh) 2016-05-16
DK3756652T3 (da) 2022-09-12
RS63567B1 (sr) 2022-10-31
RS61045B1 (sr) 2020-12-31
UY33169A (es) 2011-08-31
CA2790197A1 (en) 2011-07-14
US20160002341A1 (en) 2016-01-07
CA2790197C (en) 2017-12-12
JP2013516481A (ja) 2013-05-13
EP3409269B1 (en) 2020-08-12
EP4098247A1 (en) 2022-12-07
BR112012016618A2 (pt) 2020-06-02
PE20121687A1 (es) 2012-12-14
JP5805660B2 (ja) 2015-11-04
CY1121420T1 (el) 2020-05-29
TWI533884B (zh) 2016-05-21
CL2012001853A1 (es) 2012-11-30
DK2521536T3 (en) 2018-11-19
DOP2012000193A (es) 2012-09-30
JO3417B1 (ar) 2019-10-20
CR20120393A (es) 2012-10-30
ES2818992T3 (es) 2021-04-14
US20190002574A1 (en) 2019-01-03
ZA201205035B (en) 2013-02-27
SI2521536T1 (sl) 2018-12-31
PT2521536T (pt) 2018-11-06
LT2521536T (lt) 2018-10-10
LT3409269T (lt) 2020-10-12
EP3409269A1 (en) 2018-12-05
US20210230283A1 (en) 2021-07-29
CN102869346A (zh) 2013-01-09
TW201141518A (en) 2011-12-01
AU2011204311B2 (en) 2014-05-08
SG182283A1 (en) 2012-08-30
CO6592078A2 (es) 2013-01-02
TWI587870B (zh) 2017-06-21
MA33993B1 (fr) 2013-02-01
PT3756652T (pt) 2022-08-24
SI3409269T1 (sl) 2020-10-30
MX2012007794A (es) 2012-08-01
UA107211C2 (uk) 2014-12-10
HRP20181821T1 (hr) 2018-12-28
HRP20201428T1 (hr) 2020-11-27
PL3409269T3 (pl) 2020-12-14
HRP20221139T1 (hr) 2022-12-09
PL2521536T3 (pl) 2019-01-31
EP2521536A2 (en) 2012-11-14
LT3756652T (lt) 2022-09-12
DK3409269T3 (da) 2020-09-28
RU2012133970A (ru) 2014-02-20
MY156702A (en) 2016-03-15
GT201200223A (es) 2013-11-18
US10072086B2 (en) 2018-09-11
RS57903B1 (sr) 2019-01-31
KR101787351B1 (ko) 2017-10-19
NI201200119A (es) 2013-01-24
US11098127B2 (en) 2021-08-24
ES2688070T3 (es) 2018-10-30
WO2011085158A3 (en) 2012-03-22
JP2016020371A (ja) 2016-02-04
RU2554779C2 (ru) 2015-06-27
WO2011085158A2 (en) 2011-07-14
ES2925665T3 (es) 2022-10-19
PT3409269T (pt) 2020-09-03
AR079836A1 (es) 2012-02-22
AU2011204311A1 (en) 2012-08-02
KR20120133376A (ko) 2012-12-10
NZ601114A (en) 2014-03-28
US20110171241A1 (en) 2011-07-14
US9173880B2 (en) 2015-11-03
EP2521536B1 (en) 2018-08-01
PL3756652T3 (pl) 2022-11-07
HUE040403T2 (hu) 2019-03-28
HUE051115T2 (hu) 2021-01-28
EP2521536B9 (en) 2018-12-12
CN102869346B (zh) 2014-11-12
EP3756652B1 (en) 2022-06-22
EP3756652A1 (en) 2020-12-30
JP6053886B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
PH12019502123A1 (en) Stable antibody formulation
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CY1124844T1 (el) Φαρμακευτικο σκευασμα αντισωματος
PH12014501628B1 (en) Stabilized formulations containing anti-ang2 antibodies
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
JO3449B1 (ar) صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
CY1118702T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CR11005A (es) Formulaciones estables de anticuerpos
PH12014502429A1 (en) Stabilized formulations containing anti-dll4 antibodies
MX2021011137A (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33.
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies